We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 3,723

“I’ll Be Back;” Ninth Circuit Gives Arnold Schwarzenegger-Branded Supplement Purchasers Another Shot to Pursue UCL, FAL, CLRA and Warranty Claims
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • October 18 2018

In Durnford v. MusclePharm Corp., plaintiff Durnford asserted that the company’s “Arnold Schwarzenegger Series Iron Mass” supplements are falsely


Deterring Gaming of the Generic Drug Approval Process by the Use of Citizen Petitions
  • Cozen O'Connor
  • USA
  • October 15 2018

The FDA has recently thrown its hat into the debate between brand and generic drug manufacturers about the proper way to compete. Generics often


Even in California, Failure To Report Requires Something Reportable
  • Reed Smith LLP
  • USA
  • October 11 2018

It would seem to go without saying that for a defendant to be liable for the purported “common-law” claim of failure to report adverse events to the


Upon Further Review: The DEA Legalizes a Marijuana-Derived Drug
  • Shawe Rosenthal LLP
  • USA
  • October 10 2018

We’ve talked about this before. There is an ongoing tension between state laws decriminalizing or legalizing marijuana for medicinal purposes and


A Delaware First: Chancery Court Upholds Termination of Merger Based on MAE
  • Cozen O'Connor
  • USA
  • October 10 2018

On October 1, 2018, in Akorn, Inc. v. Fresenius Kabi AG, the Delaware Court of Chancery held for the first time that a buyer had validly terminated a


Government Urges Reversal of Third Circuit Fosamax Decision
  • Reed Smith LLP
  • USA
  • October 9 2018

We would be hard pressed to think of a recent judicial decision we have blasted as hard or often as the Third Circuit’s Fosamax opinion. We deemed it


Texas Court Smotes Church’s Promotion of Bad Medicine
  • Reed Smith LLP
  • USA
  • October 3 2018

Gather round brothers and sisters, and hear the word of the Texas Court of Appeals. Today’s sermon addresses the intersection of religion and


Delaware Court Finds “Material Adverse Effect” Allows Buyer to Terminate Merger Agreement
  • Mintz
  • USA
  • October 3 2018

In a 246-page opinion issued on October 1, 2018, the Delaware Court of Chancery ruled that German pharmaceutical company Fresenius Kabi AG validly


Delaware Court of Chancery Issues Unprecedented Material Adverse Effect Ruling
  • Pepper Hamilton LLP
  • USA
  • October 3 2018

In a first-of-its-kind post-trial opinion, the Court of Chancery ruled on October 1 in Akorn, Inc. v. Fresenius Kabi AG, C.A. No. 2018-0300-JTL, that


AmeriSourceBergen Takes another Financial Hit for Fake Pharmacy Operation Under False Claims Act
  • FisherBroyles LLP
  • USA
  • October 3 2018

In a recent announcement, the Department of Justice disclosed that AmerisourceBergen Corporation and several of its subsidiaries (collectively "ABC")